Bolt Biotherapeutics reports Q1 2026 results today with one striking data point: short sellers have largely abandoned their positions, even as the stock remains near $4.78 and the company continues to burn cash.
The most dramatic shift in the run-up is the collapse in short interest. Estimated shares short fell 70% in a single session on May 11 and are now down 81% on the week — a near-total retreat that has taken short interest to just 0.12% of the free float. Borrow availability has opened up massively as a result, with utilization dropping from a recent peak of 26% on April 23 to under 1% today. Cost to borrow has also eased, running near 4.2% versus a March high above 5%. There is no meaningful squeeze dynamic here — shorts have simply left. The RSI14 of 48.5 reflects a market sitting in neutral, neither overbought nor oversold, ahead of the print.
The bull and bear cases revolve entirely around BDC-4182, the company's lead immunotherapy candidate. Bulls point to early data showing superior anti-tumor activity versus competing Claudin-18.2 ADCs, and a revised forecast for a narrower full-year net loss of $9.54 per share — down from $12.03 — as evidence that management is tightening the ship. The only analyst actively covering the stock, HC Wainwright, maintained its Buy rating and $7.00 target back in March — a target that sits 46% above the current price at face value, though the thin coverage base limits the read-through. Bears focus on the negative enterprise value, the $3.84 per share Q4 loss, and a workforce reduction that underscores how lean the runway has become. Estimated revenue for the most recent quarter is approximately $950,000, against a net loss of $5.5 million, a ratio that signals deep pre-commercial territory. The Lake Street analyst data from August 2025 carries a $75 target that appears clearly stale or reflects a data anomaly — that figure is omitted here.
Ownership is concentrated in a small group of specialist biotech investors. Sofinnova holds 7.2% of shares. Pivotal BioVenture trimmed its position by 42,000 shares as of February. Lynx1 Capital built a new stake of 30,800 shares in Q1 2026 — one of the few clear signs of fresh institutional conviction. With just 21 known institutional holders and a market cap under $10 million, BOLT is micro-cap territory where a single data point can move the needle sharply. The four most recent earnings events all produced negative one-day reactions, ranging from -2.3% to -5.3%.
Today's print is less a financial report and more a clinical update — what investors want to know is whether BDC-4182 data holds up, and whether the cash runway projections give the company enough time to reach the next meaningful readout.
See the live data behind this article on ORTEX.
Open BOLT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
